 | • レポートコード：MRC2307A0282 • 出版社/出版日：Transparency Market Research / 2023年5月 • レポート形態：英文、PDF、292ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の市場調査資料によると、世界の眼科薬市場規模は2023年の314億ドルから2031年には528億ドルへ上り、予想期間中、年平均6.2％拡大すると予測されています。本調査資料では、眼科薬の世界市場を調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、治療クラス別（抗VEGF薬、抗緑内障薬、抗炎症薬、抗感染薬、その他）分析、疾患別（ドライアイ、緑内障、感染/炎症、網膜障害、その他）分析、投与経路別（外用、局所眼科（硝子体内）、その他）分析、製品種類別（処方薬、OTC）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などについて明らかにしています。なお、本書に記載されている企業情報には、AbbVie, Inc.、Alcon Vision LLC、Bausch Health Companies, Inc.、Bayer AG、Coherus BioSciences、F. Hoffmann-La Roche Ltd.、Novartis Pharmaceuticals Corporation、Pfizer, Inc.、Regeneron Pharmaceuticals, Inc.、Santen, Inc.などが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要洞察 ・世界の眼科薬市場規模：治療クラス別 - 抗VEGF薬の市場規模 - 抗緑内障薬の市場規模 - 抗炎症薬の市場規模 - 抗感染薬の市場規模 - その他眼科薬の市場規模 ・世界の眼科薬市場規模：疾患別 - ドライアイにおける市場規模 - 緑内障における市場規模 - 感染/炎症における市場規模 - 網膜障害における市場規模 - その他疾患における市場規模 ・世界の眼科薬市場規模：投与経路別 - 外用における市場規模 - 局所眼科（硝子体内）における市場規模 - その他投与経路における市場規模 ・世界の眼科薬市場規模：製品種類別 - 処方薬における市場規模 - OTCにおける市場規模 ・世界の眼科薬市場規模：地域別 - 北米の眼科薬市場規模 - ヨーロッパの眼科薬市場規模 - アジア太平洋の眼科薬市場規模 - 中南米の眼科薬市場規模 - 中東・アフリカの眼科薬市場規模 ・競争状況 |
Ophthalmic Drugs Market – Scope of Report
TMR’s report on the global Ophthalmic Drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Ophthalmic Drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ophthalmic Drugs market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Ophthalmic Drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ophthalmic Drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ophthalmic Drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Ophthalmic Drugs market.
The report delves into the competitive landscape of the global Ophthalmic Drugs market. Key players operating in the global Ophthalmic Drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ophthalmic Drugs market profiled in this report.
Key Questions Answered in Global Ophthalmic Drugs Market Report
• What is the sales/revenue generated by Ophthalmic Drugs across all regions during the forecast period?
• What are the opportunities in the global Ophthalmic Drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Ophthalmic Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global Ophthalmic Drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Ophthalmic Drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Ophthalmic Drugs market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ophthalmic Drugs Market Volume Forecast, by Dosage Form, 2017-2031
5. Key Insights
5.1. Disease Prevalence & Incidence rate globally with key countries
5.2. Pipeline Analysis
5.3. Key Industry Events
5.4. Covid-19 Pandemic Impact on the Industry
6. Global Ophthalmic Drugs Market Analysis and Forecast, by Therapeutic Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapeutic Class, 2017-2031
6.3.1. Anti-VEGF Agents
6.3.2. Anti-glaucoma Drugs
6.3.2.1. Alpha Agonist
6.3.2.2. Beta Blockers
6.3.2.3. Prostaglandin Analogs
6.3.2.4. Combined Medication
6.3.2.5. Others
6.3.3. Anti-inflammatory Drugs
6.3.3.1. Steroids
6.3.3.2. NSAIDs
6.3.4. Anti-infective Drugs
6.3.4.1. Anti-bacterial Drugs
6.3.4.2. Anti-fungal Drugs
6.3.4.3. Others
6.3.5. Anti-allergy Drugs
6.3.6. Others
6.4. Market Attractiveness Analysis, by Therapeutic Class
7. Global Ophthalmic Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Dry Eye
7.3.2. Glaucoma
7.3.3. Infection/Inflammation
7.3.4. Retinal Disorders
7.3.4.1. Wet AMD
7.3.4.2. Dry AMD
7.3.4.3. Diabetic Retinopathy
7.3.4.4. Others
7.3.5. Allergy
7.3.6. Uveitis
7.3.7. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Ophthalmic Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Topical
8.3.2. Local Ocular (intravitreal)
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Ophthalmic Drugs Market Analysis and Forecast, by Product Type
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Product Type, 2017-2031
9.3.1. Prescription
9.3.2. OTC
9.4. Market Attractiveness Analysis, by Product Type
10. Global Ophthalmic Drugs Market Analysis and Forecast, by Dosage Form
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Dosage Form, 2017-2031
10.3.1. Eye Drops
10.3.2. Eye Solutions & Suspensions
10.3.3. Capsules & Tablets
10.3.4. Gels
10.3.5. Ointments
10.3.6. Others
10.4. Market Attractiveness Analysis, by Dosage Form
11. Global Ophthalmic Drugs Market Analysis and Forecast, by Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness Analysis, by Distribution Channel
12. Global Ophthalmic Drugs Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region
13. North America Ophthalmic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutic Class, 2017-2031
13.2.1. Anti-VEGF Agents
13.2.2. Anti-glaucoma Drugs
13.2.2.1. Alpha Agonist
13.2.2.2. Beta Blockers
13.2.2.3. Prostaglandin Analogs
13.2.2.4. Combined Medication
13.2.2.5. Others
13.2.3. Anti-inflammatory Drugs
13.2.3.1. Steroids
13.2.3.2. NSAIDs
13.2.4. Anti-infective Drugs
13.2.4.1. Anti-bacterial Drugs
13.2.4.2. Anti-fungal Drugs
13.2.4.3. Others
13.2.5. Anti-allergy Drugs
13.2.6. Others
13.3. Market Value Forecast, by Indication, 2017-2031
13.3.1. Dry Eye
13.3.2. Glaucoma
13.3.3. Infection/Inflammation
13.3.4. Retinal Disorders
13.3.4.1. Wet AMD
13.3.4.2. Dry AMD
13.3.4.3. Diabetic Retinopathy
13.3.4.4. Others
13.3.5. Allergy
13.3.6. Uveitis
13.3.7. Others
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Topical
13.4.2. Local Ocular (intravitreal)
13.4.3. Others
13.5. Market Value Forecast, by Product Type, 2017-2031
13.5.1. Prescription
13.5.2. OTC
13.6. Market Value Forecast, by Dosage Form, 2017-2031
13.6.1. Eye Drops
13.6.2. Eye Solutions & Suspensions
13.6.3. Capsules & Tablets
13.6.4. Gels
13.6.5. Ointments
13.6.6. Others
13.7. Market Value Forecast, by Distribution Channel, 2017-2031
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Value Forecast, by Country, 2017-2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Therapeutic Class
13.9.2. By Indication
13.9.3. By Route of Administration
13.9.4. By Product Type
13.9.5. By Dosage Form
13.9.6. By Distribution Channel
13.9.7. By Country
14. Europe Ophthalmic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapeutic Class, 2017-2031
14.2.1. Anti-VEGF Agents
14.2.2. Anti-glaucoma Drugs
14.2.2.1. Alpha Agonist
14.2.2.2. Beta Blockers
14.2.2.3. Prostaglandin Analogs
14.2.2.4. Combined Medication
14.2.2.5. Others
14.2.3. Anti-inflammatory Drugs
14.2.3.1. Steroids
14.2.3.2. NSAIDs
14.2.4. Anti-infective Drugs
14.2.4.1. Anti-bacterial Drugs
14.2.4.2. Anti-fungal Drugs
14.2.4.3. Others
14.2.5. Anti-allergy Drugs
14.2.6. Others
14.3. Market Value Forecast, by Indication, 2017-2031
14.3.1. Dry Eye
14.3.2. Glaucoma
14.3.3. Infection/Inflammation
14.3.4. Retinal Disorders
14.3.4.1. Wet AMD
14.3.4.2. Dry AMD
14.3.4.3. Diabetic Retinopathy
14.3.4.4. Others
14.3.5. Allergy
14.3.6. Uveitis
14.3.7. Others
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Topical
14.4.2. Local Ocular (intravitreal)
14.4.3. Others
14.5. Market Value Forecast, by Product Type, 2017-2031
14.5.1. Prescription
14.5.2. OTC
14.6. Market Value Forecast, by Dosage Form, 2017-2031
14.6.1. Eye Drops
14.6.2. Eye Solutions & Suspensions
14.6.3. Capsules & Tablets
14.6.4. Gels
14.6.5. Ointments
14.6.6. Others
14.7. Market Value Forecast, by Distribution Channel, 2017-2031
14.7.1. Hospital Pharmacies
14.7.2. Retail Pharmacies
14.7.3. Online Pharmacies
14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Therapeutic Class
14.9.2. By Indication
14.9.3. By Route of Administration
14.9.4. By Product Type
14.9.5. By Dosage Form
14.9.6. By Distribution Channel
14.9.7. By Country/Sub-region
15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapeutic Class, 2017-2031
15.2.1. Anti-VEGF Agents
15.2.2. Anti-glaucoma Drugs
15.2.2.1. Alpha Agonist
15.2.2.2. Beta Blockers
15.2.2.3. Prostaglandin Analogs
15.2.2.4. Combined Medication
15.2.2.5. Others
15.2.3. Anti-inflammatory Drugs
15.2.3.1. Steroids
15.2.3.2. NSAIDs
15.2.4. Anti-infective Drugs
15.2.4.1. Anti-bacterial Drugs
15.2.4.2. Anti-fungal Drugs
15.2.4.3. Others
15.2.5. Anti-allergy Drugs
15.2.6. Others
15.3. Market Value Forecast, by Indication, 2017-2031
15.3.1. Dry Eye
15.3.2. Glaucoma
15.3.3. Infection/Inflammation
15.3.4. Retinal Disorders
15.3.4.1. Wet AMD
15.3.4.2. Dry AMD
15.3.4.3. Diabetic Retinopathy
15.3.4.4. Others
15.3.5. Allergy
15.3.6. Uveitis
15.3.7. Others
15.4. Market Value Forecast, by Route of Administration, 2017-2031
15.4.1. Topical
15.4.2. Local Ocular (intravitreal)
15.4.3. Others
15.5. Market Value Forecast, by Product Type, 2017-2031
15.5.1. Prescription
15.5.2. OTC
15.6. Market Value Forecast, by Dosage Form, 2017-2031
15.6.1. Eye Drops
15.6.2. Eye Solutions & Suspensions
15.6.3. Capsules & Tablets
15.6.4. Gels
15.6.5. Ointments
15.6.6. Others
15.7. Market Value Forecast, by Distribution Channel, 2017-2031
15.7.1. Hospital Pharmacies
15.7.2. Retail Pharmacies
15.7.3. Online Pharmacies
15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Therapeutic Class
15.9.2. By Indication
15.9.3. By Route of Administration
15.9.4. By Product Type
15.9.5. By Dosage Form
15.9.6. By Distribution Channel
15.9.7. By Country/Sub-region
16. Latin America Ophthalmic Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Therapeutic Class, 2017-2031
16.2.1. Anti-VEGF Agents
16.2.2. Anti-glaucoma Drugs
16.2.2.1. Alpha Agonist
16.2.2.2. Beta Blockers
16.2.2.3. Prostaglandin Analogs
16.2.2.4. Combined Medication
16.2.2.5. Others
16.2.3. Anti-inflammatory Drugs
16.2.3.1. Steroids
16.2.3.2. NSAIDs
16.2.4. Anti-infective Drugs
16.2.4.1. Anti-bacterial Drugs
16.2.4.2. Anti-fungal Drugs
16.2.4.3. Others
16.2.5. Anti-allergy Drugs
16.2.6. Others
16.3. Market Value Forecast, by Indication, 2017-2031
16.3.1. Dry Eye
16.3.2. Glaucoma
16.3.3. Infection/Inflammation
16.3.4. Retinal Disorders
16.3.4.1. Wet AMD
16.3.4.2. Dry AMD
16.3.4.3. Diabetic Retinopathy
16.3.4.4. Others
16.3.5. Allergy
16.3.6. Uveitis
16.3.7. Others
16.4. Market Value Forecast, by Route of Administration, 2017-2031
16.4.1. Topical
16.4.2. Local Ocular (intravitreal)
16.4.3. Others
16.5. Market Value Forecast, by Product Type, 2017-2031
16.5.1. Prescription
16.5.2. OTC
16.6. Market Value Forecast, by Dosage Form, 2017-2031
16.6.1. Eye Drops
16.6.2. Eye Solutions & Suspensions
16.6.3. Capsules & Tablets
16.6.4. Gels
16.6.5. Ointments
16.6.6. Others
16.7. Market Value Forecast, by Distribution Channel, 2017-2031
16.7.1. Hospital Pharmacies
16.7.2. Retail Pharmacies
16.7.3. Online Pharmacies
16.8. Market Value Forecast, by Country/Sub-region,2017-2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Therapeutic Class
16.9.2. By Indication
16.9.3. By Route of Administration
16.9.4. By Product Type
16.9.5. By Dosage Form
16.9.6. By Distribution Channel
16.9.7. By Country/Sub-region
17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Therapeutic Class, 2017-2031
17.2.1. Anti-VEGF Agents
17.2.2. Anti-glaucoma Drugs
17.2.2.1. Alpha Agonist
17.2.2.2. Beta Blockers
17.2.2.3. Prostaglandin Analogs
17.2.2.4. Combined Medication
17.2.2.5. Others
17.2.3. Anti-inflammatory Drugs
17.2.3.1. Steroids
17.2.3.2. NSAIDs
17.2.4. Anti-infective Drugs
17.2.4.1. Anti-bacterial Drugs
17.2.4.2. Anti-fungal Drugs
17.2.4.3. Others
17.2.5. Anti-allergy Drugs
17.2.6. Others
17.3. Market Value Forecast, by Indication, 2017-2031
17.3.1. Dry Eye
17.3.2. Glaucoma
17.3.3. Infection/Inflammation
17.3.4. Retinal Disorders
17.3.4.1. Wet AMD
17.3.4.2. Dry AMD
17.3.4.3. Diabetic Retinopathy
17.3.4.4. Others
17.3.5. Allergy
17.3.6. Uveitis
17.3.7. Others
17.4. Market Value Forecast, by Route of Administration, 2017-2031
17.4.1. Topical
17.4.2. Local Ocular (intravitreal)
17.4.3. Others
17.5. Market Value Forecast, by Product Type, 2017-2031
17.5.1. Prescription
17.5.2. OTC
17.6. Market Value Forecast, by Dosage Form, 2017-2031
17.6.1. Eye Drops
17.6.2. Eye Solutions & Suspensions
17.6.3. Capsules & Tablets
17.6.4. Gels
17.6.5. Ointments
17.6.6. Others
17.7. Market Value Forecast, by Distribution Channel, 2017-2031
17.7.1. Hospital Pharmacies
17.7.2. Retail Pharmacies
17.7.3. Online Pharmacies
17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Therapeutic Class
17.9.2. By Indication
17.9.3. By Route of Administration
17.9.4. By Product Type
17.9.5. By Dosage Form
17.9.6. By Distribution Channel
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player – Competition Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company, 2022
18.3. Company Profiles
18.3.1. AbbVie, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Alcon Vision LLC
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. Bausch Health Companies, Inc.
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Bayer AG
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. Coherus BioSciences
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.5.5. Strategic Overview
18.3.6. F. Hoffmann-La Roche Ltd.
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Novartis Pharmaceuticals Corporation
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Pfizer, Inc.
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. Regeneron Pharmaceuticals, Inc.
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Santen, Inc.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview
18.3.11. Sun Pharmaceutical Industries Ltd.
18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.11.2. Product Portfolio
18.3.11.3. Financial Overview
18.3.11.4. SWOT Analysis
18.3.11.5. Strategic Overview
18.3.12. Teva Pharmaceutical Industries Ltd.
18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.12.2. Product Portfolio
18.3.12.3. Financial Overview
18.3.12.4. SWOT Analysis
18.3.12.5. Strategic Overview
Table 01: Global Ophthalmic Drugs Market Volume (Prescriptions in Mn) Forecast, by Dosage Form, 2017-2031
Table 02: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 03: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 04: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 05: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 06: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 07: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 08: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 09: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 10: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 11: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 12: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 13: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 14: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 15: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 16: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 17: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 18: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 19: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 20: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 21: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 22: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 23: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 25: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 26: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 27: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 28: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 29: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 30: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 31: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 32: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 33: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 34: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 35: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 36: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 37: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 38: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 39: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 40: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 41: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 42: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 43: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 44: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 45: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 46: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 47: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 48: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 49: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 50: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 51: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 52: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 53: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 54: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 55: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 56: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 57: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 58: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 59: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 60: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 61: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 62: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 63: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 64: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 65: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 66: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 67: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031